(ARDX) Ardelyx - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.464m USD | Total Return: 40.9% in 12m
IBS Therapy, Phosphate Reducer, Gastrointestinal Drug, Dialysis Support
Total Rating 34
Safety 32
Buy Signal -0.19
Biotechnology
Industry Rotation: +6.6
Industry Rotation: +6.6
Market Cap:
1.46B
Avg Turnover: 15.9M USD
Avg Turnover: 15.9M USD
ATR:
4.97%
Peers RS (IBD): 28.7
Peers RS (IBD): 28.7
Risk 5d forecast
Volatility74.6%
Rel. Tail Risk-21.6%
Reward TTM
Sharpe Ratio0.74
Alpha10.70
Character TTM
Beta0.615
Beta Downside2.105
Drawdowns 3y
Max DD66.32%
CAGR/Max DD0.16
EPS (Earnings per Share)
EPS CAGR: 140.91%
EPS Trend: 44.1%
EPS Trend: 44.1%
Last SUE: 0.57
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 343.92%
Rev. Trend: 85.3%
Rev. Trend: 85.3%
Last SUE: 0.90
Qual. Beats: 1
Qual. Beats: 1
Warnings
Interest Coverage Ratio -1.1 is critical
Altman Z'' -5.73 < 1.0 - financial distress zone
Volatile
Tailwinds
No distinct edge detected
Description: ARDX Ardelyx
Ardelyx, Inc. (NASDAQ: ARDX) is a biotechnology company focused on discovering, developing, and commercializing therapies for unmet medical needs, primarily in the United States. Its current product portfolio includes IBSRELA, a minimally absorbed small-molecule treatment for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor aimed at lowering serum phosphorus in dialysis-dependent chronic kidney disease patients. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx rebranded from Nteryx in 2008.
As of the latest quarter (Q4 2025), Ardelyx reported $112 million in total revenue, driven largely by IBSRELA sales, and maintained a cash runway of approximately $210 million, supporting ongoing Phase 3 trials for XPHOZAH. The dialysis market is projected to grow at a 4.2% CAGR through 2030, bolstering demand for phosphate binders, while the IBS-C segment benefits from increasing awareness and a 2.8% annual rise in diagnosed cases. R&D intensity remains high, with 28% of revenue reinvested into pipeline development, reflecting the sector’s emphasis on innovative, niche therapeutics.
For a deeper quantitative view, consider exploring ValueRay’s analytics platform.
- IBSRELA sales growth impacts revenue forecasts
- XPHOZAH launch success critical for market penetration
- Clinical trial outcomes influence regulatory approvals
- Competition from new kidney disease treatments poses risk
- Healthcare policy changes affect drug pricing and reimbursement
Piotroski VR‑10 (Strict)
3.0
| Net Income: -61.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 72.11% < 20% (prev 83.52%; Δ -11.41% < -1%) |
| CFO/TA -0.08 > 3% & CFO -42.5m > Net Income -61.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (243.6m) vs 12m ago -0.18% < -2% |
| Gross Margin: 90.29% > 18% (prev 0.85%; Δ 8.94k% > 0.5%) |
| Asset Turnover: 86.80% > 50% (prev 76.56%; Δ 10.24% > 0%) |
| Interest Coverage Ratio: -1.14 > 6 (EBITDA TTM -29.2m / Interest Expense TTM 28.4m) |
Altman Z''
-5.73
| A: 0.58 (Total Current Assets 382.3m - Total Current Liabilities 88.6m) / Total Assets 502.8m |
| B: -1.88 (Retained Earnings -946.9m / Total Assets 502.8m) |
| C: -0.07 (EBIT TTM -32.2m / Avg Total Assets 469.3m) |
| D: -2.82 (Book Value of Equity -946.7m / Total Liabilities 335.9m) |
| Altman-Z'' Score: -5.73 = D |
Beneish M
-2.77
| DSRI: 1.02 (Receivables 71.8m/57.7m, Revenue 407.3m/333.6m) |
| GMI: 0.94 (GM 90.29% / 84.55%) |
| AQI: 1.30 (AQ_t 0.23 / AQ_t-1 0.17) |
| SGI: 1.22 (Revenue 407.3m / 333.6m) |
| TATA: -0.04 (NI -61.6m - CFO -42.5m) / TA 502.8m) |
| Beneish M-Score: -2.77 (Cap -4..+1) = A |
What is the price of ARDX shares?
As of April 09, 2026, the stock is trading at USD 6.10 with a total of 3,032,884 shares traded.
Over the past week, the price has changed by -0.16%, over one month by -1.13%, over three months by -12.86% and over the past year by +40.88%.
Over the past week, the price has changed by -0.16%, over one month by -1.13%, over three months by -12.86% and over the past year by +40.88%.
Is ARDX a buy, sell or hold?
Ardelyx has received a consensus analysts rating of 4.64.
Therefore, it is recommended to buy ARDX.
- StrongBuy: 8
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARDX price?
| Analysts Target Price | 16.1 | 163.9% |
Ardelyx (ARDX) - Fundamental Data Overview
as of 08 April 2026
P/E Forward = 33.0033 P/S = 3.5945
P/B = 8.7405
P/EG = -0.08
Revenue TTM = 407.3m USD
EBIT TTM = -32.2m USD
EBITDA TTM = -29.2m USD
Long Term Debt = 202.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.48m USD (from shortTermDebt, last quarter)
Debt = 211.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.1m USD (recalculated: Debt 211.6m - CCE 264.7m)
Enterprise Value = 1.41b USD (1.46b + Debt 211.6m - CCE 264.7m)
Interest Coverage Ratio = -1.14 (Ebit TTM -32.2m / Interest Expense TTM 28.4m)
EV/FCF = -32.09x (Enterprise Value 1.41b / FCF TTM -44.0m)
FCF Yield = -3.12% (FCF TTM -44.0m / Enterprise Value 1.41b)
FCF Margin = -10.80% (FCF TTM -44.0m / Revenue TTM 407.3m)
Net Margin = -15.12% (Net Income TTM -61.6m / Revenue TTM 407.3m)
Gross Margin = 90.29% ((Revenue TTM 407.3m - Cost of Revenue TTM 39.5m) / Revenue TTM)
Gross Margin QoQ = 89.21% (prev none%)
Tobins Q-Ratio = 2.81 (Enterprise Value 1.41b / Total Assets 502.8m)
Interest Expense / Debt = 4.61% (Interest Expense 9.77m / Debt 211.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.5m (EBIT -32.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.31 (Total Current Assets 382.3m / Total Current Liabilities 88.6m)
Debt / Equity = 1.27 (Debt 211.6m / totalStockholderEquity, last quarter 166.9m)
Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -53.1m / EBITDA -29.2m)
Debt / FCF = 1.21 (negative FCF - burning cash) (Net Debt -53.1m / FCF TTM -44.0m)
Total Stockholder Equity = 151.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.13% (Net Income -61.6m / Total Assets 502.8m)
RoE = -40.63% (Net Income TTM -61.6m / Total Stockholder Equity 151.6m)
RoCE = -9.09% (EBIT -32.2m / Capital Employed (Equity 151.6m + L.T.Debt 202.8m))
RoIC = -7.47% (negative operating profit) (NOPAT -25.5m / Invested Capital 341.0m)
WACC = 7.58% (E(1.46b)/V(1.68b) * Re(8.15%) + D(211.6m)/V(1.68b) * Rd(4.61%) * (1-Tc(0.21)))
Discount Rate = 8.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 5.39%
[DCF] Fair Price = unknown (Cash Flow -44.0m)
EPS Correlation: 44.07 | EPS CAGR: 140.9% | SUE: 0.57 | # QB: 0
Revenue Correlation: 85.34 | Revenue CAGR: 343.9% | SUE: 0.90 | # QB: 1
EPS next Quarter (2026-06-30): EPS=-0.03 | Chg7d=+0.000 | Chg30d=-0.063 | Revisions Net=-4 | Analysts=6
EPS current Year (2026-12-31): EPS=0.01 | Chg7d=+0.000 | Chg30d=-0.180 | Revisions Net=-4 | Growth EPS=+104.9% | Growth Revenue=+34.9%
EPS next Year (2027-12-31): EPS=0.52 | Chg7d=+0.000 | Chg30d=-0.158 | Revisions Net=-3 | Growth EPS=+4012.1% | Growth Revenue=+34.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
External Resources